title: Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans.
abstract: BACKGROUND
  Aldosterone stimulation by angiotensin II may not exclusively be mediated by the angiotensin II type 1 (AT(1)) receptor. We have, therefore, investigated the vascular and adrenal response to angiotensin II infusion without and with pretreatment with the AT(1) receptor antagonist valsartan (160 mg).
  
  
  METHODS
  In nine healthy human volunteers, angiotensin II was administered intravenously at doses of 1, 3, and 10 ng/kg/min, each over 45 min. Arterial blood pressure (BP) was measured oscillometrically at 5-min intervals. Blood for the determination of plasma renin activity and aldosterone was taken before the start of the infusion, at the end of each infusion period, and 1 h after the infusion was stopped.
  
  
  RESULTS
  Angiotensin II increased systolic and diastolic BP from 121 +/- 3/70 +/- 2 mm Hg to a maximum of 146 +/- 2/97 +/- 1 mm Hg (P <.001) and plasma aldosterone from 39.2 +/- 9.8 to 290.7 +/- 48.3 (P <.001). The increase in BP after exogenous angiotensin II was completely abolished in volunteers pretreated with valsartan, averaging 118 +/- 3/72 +/- 1 mm Hg by the end of the maximum angiotensin infusion dose. In contrast, plasma aldosterone stimulation by angiotensin II was only partially blunted by concomitant AT(1) receptor blockade (98.9 +/- 16.3 pg/mL after the maximal dose of angiotensin II).
  
  
  CONCLUSIONS
  These results indicate that although the vascular response to exogenous angiotensin II is exclusively mediated by the AT(1) receptor, the effects of angiotensin II on adrenal aldosterone release may involve other pathways.
authors.affiliation: Medizinische Universitäts-Poliklinik, Bonn, Germany.
authors.forename: Katja
authors.initials: K
authors.lastname: Lottermoser
authors.forename: Thomas
authors.initials: T
authors.lastname: Unger
authors.forename: Peter
authors.initials: P
authors.lastname: Gohlke
authors.forename: Hans
authors.initials: H
authors.lastname: Vetter
authors.forename: Rainer
authors.initials: R
authors.lastname: Düsing
mesh_terms: D000311:Adrenal Glands / Q000187:drug effects* / Q000378:metabolism; D000328:Adult; D000450:Aldosterone / Q000097:blood; D000804:Angiotensin II / Q000008:administration & dosage*; D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents / Q000008:administration & dosage; D001794:Blood Pressure / Q000187:drug effects*; D016232:Endothelins / Q000097:blood; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007275:Injections, Intravenous; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D012083:Renin / Q000097:blood; D013777:Tetrazoles / Q000008:administration & dosage; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives; D000068756:Valsartan; D014662:Vasoconstrictor Agents / Q000008:administration & dosage*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D016232:Endothelins; D015850:Interleukin-6; D013777:Tetrazoles; D014409:Tumor Necrosis Factor-alpha; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D000450:Aldosterone; D000068756:Valsartan; D012083:Renin; D014633:Valine; D006854:Hydrocortisone